KURAKura’s combo gets a fresh spotlight
Kura Oncology and Kyowa Kirin aren’t just tossing out a conference slide deck and calling it a day. They published updated KOMET-007 data in Blood, and the headline is basically: ziftomenib plus venetoclax/azacitidine is still looking like a serious contender in a tough blood cancer setting.
The numbers are doing a lot of the talking
At the recommended 600 mg once-daily dose, the combo posted:
- 87% overall response rate and 70% CRc in venetoclax-naïve patients
- 48% ORR and 24% CRc in venetoclax-experienced patients
- Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure
- Median overall survival not reached after 10.7 months of follow-up in the venetoclax-naïve group
That’s not just “the science is interesting” territory. That’s the kind of data that can move the market’s imagination from maybe to hmm, okay, now we’re listening.
Why investors should care
For Kura, this is all about de-risking ziftomenib and making the case that it can be more than a one-trick biotech pony. A strong safety profile matters too — low rates of differentiation syndrome and QTc prolongation make the combo look a lot less like a cliffhanger and a lot more like a viable development path.
Kyowa Kirin gets a mention here because partnerships in biotech are basically the corporate version of "I’ll bring the science, you bring the global reach." If the data keeps holding up, the commercial and strategic value of the collaboration only gets shinier.
Big picture
Biotech investors know the drill: one great data point doesn’t equal a home run. But when a published study shows strong responses, durable benefit, and tolerable safety, the market tends to stop doom-scrolling and start modeling upside.